SEC Form 4 · accession 0001209191-18-034172
Iterum Therapeutics plc · ITRM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael W. Dunne
Officer — Chief Scientific Officer
Period of report
May 30, 2018
Accepted (ET)
May 30, 2018 · 5:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001659323
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | May 30, 2018 | C | 12,730 | — | A | 137,491 | D | |
| Ordinary SharesF2 | May 30, 2018 | C | 4,050 | — | A | 141,541 | D | |
| Ordinary SharesF3 | May 30, 2018 | C | 2,917 | — | A | 144,458 | D | |
| Ordinary Shares | May 30, 2018 | P | 2,000 | $13.00 | A | 146,458 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A Preferred SharesF1,F4 | — | May 30, 2018 | C | 12,730 | D | — | — | Ordinary Shares | 12,730 | 0 | D |
| Series B-1 Preferred SharesF2,F4 | — | May 30, 2018 | C | 4,050 | D | — | — | Ordinary Shares | 4,050 | 0 | D |
| Series B-2 Preferred SharesF3,F4 | — | May 30, 2018 | C | 2,917 | D | — | — | Ordinary Shares | 2,917 | 0 | D |
Explanation of responses
- F1The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.
- F2The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.
- F3The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.
- F4Not applicable.